Keywords: Contrast Agents, Contrast Mechanisms, Ferumoxytol
Motivation: Ferumoxytol is becoming more widely used as a contrast agent, yet the optimum dose for use in cardiac MRI remains unknown.
Goal(s): To evaluate whether reducing the contrast dose to 2 or 1mg/kg will affect the image quality and diagnostic accuracy.
Approach: Forty-five patients with complex congenital heart disease had a 3D-IR-SSFP sequence performed at two different ferumoxytol doses. Twenty were in the ferumoxytol 1 vs. 2 mg/kg group, and twenty-five in the 2 vs. 3 mg/kg group.
Results: There was no significant difference in the RCA image quality score, RCA length, diagnostic accuracy nor CNR with the use of the reduced dosing.
Impact: Using reduced ferumoxytol dosing (1 or 2mg/kg), may lead to comparable image quality and diagnostic performance. The use of 2mg/kg lowers blood-T1 time to the extent that systolic imaging should not be precluded with the current 3D-IR Whole Heart Sequences.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords